Ibogaine – a psychedelic compound extracted from the root bark of an African shrub called iboga – spent decades on the margins of American medicine, too strange and too Schedule I to attract mainstream political attention. Then Bryan Hubbard got involved, and the Republican Party started paying attention.
The Activist Who Moved the Needle
Bryan Hubbard is a conservative activist, not a scientist or a clinician. His background is in political organizing, not pharmacology. Yet he became the central figure in a quiet but effective campaign to bring ibogaine into the Republican mainstream – a campaign that eventually reached Donald Trump and reshaped how the G.O.P. talks about addiction treatment.
Hubbard’s push centered on ibogaine’s potential as a treatment for opioid addiction, particularly among veterans. The drug has shown promise in interrupting opioid dependence, with some studies and anecdotal reports pointing to dramatic reductions in withdrawal symptoms and cravings after a single dose. That framing – not ibogaine as a counterculture experience, but ibogaine as a tool for healing broken veterans – gave Hubbard a politically viable entry point into conservative circles that would otherwise have slammed the door on any psychedelic conversation.
He found allies quickly. Rick Perry, the former Texas governor and former U.S. Secretary of Energy under Trump, became one of the more prominent voices lending credibility to Hubbard’s cause. Perry’s support brought the issue a degree of institutional Republican weight that no amount of wellness-community advocacy could have manufactured. A former governor publicly backing a psychedelic drug for veteran treatment is not a small thing – it signals to the broader party that this is not a hippie project dressed up in clinical language.
Joe Rogan’s involvement added a different kind of reach. Rogan’s podcast regularly pulls in audiences that skew male, politically mixed to right-leaning, and deeply interested in biohacking, veteran issues, and alternative medicine. When Rogan took up ibogaine as a topic – framing it less as drug legalization and more as a suppressed medical treatment – it reached millions of listeners who would never have encountered the issue through traditional policy channels. Rogan’s audience doesn’t need to be convinced that government health agencies have missed things. They already believe it.
Psychedelics and the Political Realignment Nobody Predicted
For most of its American history, psychedelic advocacy lived on the left. The cultural lineage ran from Timothy Leary through the counterculture through the therapeutic renaissance of the 1990s and 2000s, and the people pushing for psilocybin decriminalization or MDMA therapy were, broadly, not Republicans. Ibogaine was even further out – used in West African Bwiti spiritual ceremonies, largely illegal in the U.S., associated with intense and sometimes dangerous multi-hour experiences. It was not obvious political territory for a party that spent decades running on tough-on-drugs messaging.
What changed is partly about veterans. The opioid crisis devastated military communities, and conventional addiction medicine has not solved it. Methadone and buprenorphine maintenance therapies work for many people, but they don’t work for everyone, and within veteran communities there is a specific and intense frustration with the V.A.’s limitations. Ibogaine became interesting to a subset of veterans precisely because it sits outside the pharmaceutical mainstream – and in right-leaning political culture, skepticism of that mainstream is now a baseline assumption rather than a fringe position.
The political packaging matters enormously here. Hubbard and his allies did not try to legalize ibogaine broadly or argue for psychedelic experiences as inherently valuable. They argued for a specific medical application for a specific population – veterans with opioid addiction – and they argued that regulatory barriers were blocking a treatment that could save lives. That argument lands differently than “decriminalize all psychedelics.” It fits into an existing conservative framework about government overreach into medical decision-making, a framework that has only grown stronger since the COVID-19 pandemic amplified distrust of federal health institutions.
Trump’s embrace of ibogaine – or at least his openness to the conversation – reflects how thoroughly the Republican Party’s relationship to both drug policy and medical establishment skepticism has shifted. A decade ago, a Republican president publicly engaging with psychedelic treatment would have been politically untenable. Now, with figures like Perry providing institutional cover and Rogan providing cultural cover, the calculation looks different. The constituency for this position is real, it is growing, and it is largely male, largely veteran-adjacent, and already disposed to trust alternative medicine narratives over F.D.A. consensus.
Ibogaine itself is derived from Tabernanthe iboga, a shrub native to Central Africa. The compound is a powerful dissociative hallucinogen that produces experiences lasting anywhere from twelve to twenty-four hours. It carries cardiac risks – several deaths have been associated with its use – which is one reason why medical supervision is considered essential and why formal clinical trials in the U.S. have been slow to develop. Its legal status remains complicated: classified as a Schedule I substance under federal law, meaning the government formally considers it to have no accepted medical use and high abuse potential, a designation that ibogaine advocates argue is both outdated and politically motivated.
What the G.O.P. Embrace Actually Changes
Whether Republican support translates into concrete policy movement is the live question. Hubbard’s campaign has been effective at generating attention and shifting the tone of the conversation inside certain conservative circles, but attention is not legislation. Ibogaine still faces real regulatory and scientific hurdles – the cardiac risk profile alone makes clinical trial design complicated, and the F.D.A. approval pathway for a Schedule I substance is neither fast nor cheap.
What the political realignment does change is who gets to be in the room. When ibogaine research was associated primarily with progressive drug-reform organizations, it had limited access to the Republican-controlled levers of federal health policy. With Perry and Hubbard and Rogan pulling in the same direction, and with Trump at minimum not pushing back, the conversation now has access to a different set of corridors. Republican congressional dynamics are already fracturing along unexpected lines, and ibogaine is now one of the stranger fault lines – a drug derived from an African shrub, traveling through veteran advocacy networks and conservative podcasting, landing somewhere nobody in either the psychedelic research community or the Republican Party would have predicted five years ago. The veterans who took ibogaine in clinics in Mexico and came back saying it saved their lives are still waiting to find out whether any of this political momentum actually produces something they can access legally at home.
